Janet Jill Hopkins - Nov 1, 2023 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role: Chief Medical Officer
Signature: /s/ Julie Feder, Attorney-in-fact
Stock symbol: AURA
Transactions as of: Nov 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 11/3/2023, 05:04 PM
Previous filing: Oct 23, 2023
Next filing: Feb 2, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AURA	Common Stock	Award	$0	+135K		$0.00	135K	Nov 1, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AURA	Stock Option (Right to Buy)	Award	$0	+200K		$0.00	200K	Nov 1, 2023	Common Stock	200K	$8.97	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Company's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Company's common stock. These RSUs vest in four substantially equal annual installments beginning on November 15, 2024, subject to the Reporting Person's continued service as of each such vesting date.
F2	The shares underlying this option vest as follows: 25% of the shares vest on October 16, 2024 with the remainder vesting thereafter in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.